Teva Pharmaceutical (TEVA) Tops Q1 EPS by 2c

Teva Pharmaceutical (NYSE: TEVA) reported Q1 EPS of $1.22, $0.02 better than the analyst estimate of $1.20. Revenue for the quarter came in at $5 billion versus the consensus estimate of $5.11 billion.

For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Evolution Petroleum closes $16M Midland Basin royalty acquisition
• China semiconductor equipment imports grow 9% in July, Barclays comments